<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003131</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-MTFOA-001</org_study_id>
    <nct_id>NCT02003131</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis</brief_title>
  <official_title>Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic mesenchymal trophic factors (MTF) from human umbilical cord tissue-derived&#xD;
      mesenchymal stem cells (UC-MSC) injected into the knee joints of 20 patients (group 1) or&#xD;
      injected subcutaneously into 20 patients (group 2) is a safe and useful procedure for&#xD;
      inducing joint function improvements in osteoarthritis (OA) patients with grade 2, 3, or 4&#xD;
      radiographic OA severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will assess primary safety and secondary efficacy endpoints of allogeneic&#xD;
      UC-MSC-derived MTF administered to two arms osteoarthritis patients with grade 2, 3, or 4&#xD;
      radiographic OA severity (20 per arm). The first arm will receive an intra-articular&#xD;
      injection of MTF into the knee joint under fluoroscopy. The second arm will receive 12&#xD;
      subcutaneous MTF injections, once per week.&#xD;
&#xD;
      For both arms, the primary objective of safety will be defined as freedom from treatment&#xD;
      associated adverse events for the period of one year. The secondary objective of efficacy&#xD;
      will include evaluation at baseline and at months 3 and 12 of efficacy endpoints of joint&#xD;
      function improvement as assessed by Western Ontario and McMaster Universities Osteoarthritis&#xD;
      Index (WOMAC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment&#xD;
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in joint function from baseline WOMAC assessment at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Intra-articular knee injection of MTF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous injection of MTF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trophic factors from umbilical cord mesenchymal stem cells</intervention_name>
    <arm_group_label>Intra-articular knee injection of MTF</arm_group_label>
    <arm_group_label>Subcutaneous injection of MTF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years and ability to understand the planned treatment.&#xD;
&#xD;
          -  Subjects 18 years of age or older with idiopathic or secondary osteoarthritis of the&#xD;
             knee with grade 2, 3, or 4 radiographic severity, as defined by the modified&#xD;
             Kellgren-Lawrence classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or cognitively impaired adults.&#xD;
&#xD;
          -  Presence of large meniscal tears (&quot;bucket handle&quot; tears), as detected by clinical&#xD;
             examination or by magnetic resonance imaging.&#xD;
&#xD;
          -  Inflammatory or post infectious arthritis.&#xD;
&#xD;
          -  More than 5 degrees of varus or valgus deformity.&#xD;
&#xD;
          -  Kellgren Lawrence grade 4 osteoarthritis in two compartments (the medial or lateral&#xD;
             compartments of the tibiofemoral joint or the patellofemoral compartment) in persons&#xD;
             over 60 years of age.&#xD;
&#xD;
          -  Intra-articular corticosteroid injection within the previous 3 months.&#xD;
&#xD;
          -  A major neurologic deficit.&#xD;
&#xD;
          -  Serious medical illness with a life expectancy of less than 1 year.&#xD;
&#xD;
          -  Prior admission for substance abuse&#xD;
&#xD;
          -  Body Mass Index (BMI) of 40 kg/m2 or greater&#xD;
&#xD;
          -  Patient receiving experimental medication or participating in another clinical study&#xD;
             within 30 days of signing the informed consent&#xD;
&#xD;
          -  In the opinion of the investigator or the sponsor the patient is unsuitable for&#xD;
             cellular therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Paz-Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Biosciences / Stem Cell Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stem Cell Institute</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>umbilical cord</keyword>
  <keyword>mesenchymal</keyword>
  <keyword>stem cells</keyword>
  <keyword>trophic factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

